Develop a biomarker test to track disease activity in MS patients

Professor Rodney Scott

Hunter Medical Research Institute, University of Newcastle, NSW

| Better treatments | Immunology | Incubator | 2021 | Investigator Led Research |
SUPPORT PROJECTS WITH THIS RESEARCH FOCUS

Summary

Diagnosing Multiple Sclerosis (MS) is complex and often relies on exclusion of other diseases rather than having a specific test for MS.  Diagnosis is based primarily on magnetic resonance imaging (MRI) and clinical history. Once MS has been diagnosed, monitoring disease activity is also challenging and similarly relies heavily on MRIs. MRI cannot predict the development of new brain lesions or relapse in advance, but only reflects disease activity once it has occurred. More recent developments to monitor disease activity in MS include blood tests for levels of a protein called neurofilament light that reflect damage to the central nervous system. These tests, however, are not specific to MS, and will detect any damage to the brain and spinal cord, which can hamper their interpretation when it comes to diagnosing and monitoring MS.

This project will investigate whether “cell free DNA” (cfDNA; or DNA floating in body fluids) has potential as a new biological marker or “biomarker” of disease activity in MS. The team will use a test for 3 specific cfDNAs that are unique to oligodendrocytes, the brain cells that are the target of the autoimmune attack in MS. They will test whether these are higher in the cerebrospinal fluid and the blood of people with MS than in another (unrelated) neurological disease. They will also test whether these cfDNAs are more specific to MS than neurofilament light, and whether their levels are related to MS severity or predict current or future disease activity.

It is hoped that improved monitoring of disease activity will ultimately enable prevention or better management of disease relapses, thus minimising irreversible damage to brain and spinal cord.

Updated 20 January 2021

Updated: 19 January, 2021

Stages of the research process

Fundamental laboratory
Research

Laboratory research that investigates scientific theories behind the possible causes, disease progression, ways to diagnose and better treat MS.

Lab to clinic timeline: 10+ years
Translational
Research

Research that builds on fundamental scientific research to develop new therapies, medical procedures or diagnostics and advances it closer to the clinic.

Lab to clinic timeline: 5+ years
Clinical Studies
and Clinical Trials

Clinical research is the culmination of fundamental and translational research turning those research discoveries into treatments and interventions for people with MS.

Lab to clinic timeline: 1-5 years

Investigator

Co-investigator

Grant Awarded

  • Incubator Grant

Total Funding

  • $22,492

Duration

  • 1 year

Read More
mr-ali-afrasiabi-1dr-malini-visweswaran

Newsletter subscription

  • Enter your details

Develop a biomarker test to track disease activity in MS patients